217 related articles for article (PubMed ID: 15026338)
21. RANK Expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of bone.
Atkins GJ; Kostakis P; Vincent C; Farrugia AN; Houchins JP; Findlay DM; Evdokiou A; Zannettino AC
J Bone Miner Res; 2006 Sep; 21(9):1339-49. PubMed ID: 16939392
[TBL] [Abstract][Full Text] [Related]
22. Osteoclast-like cell formation by circulating myeloma B lymphocytes: role of RANK-L.
Calvani N; Silvestris F; Cafforio P; Dammacco F
Leuk Lymphoma; 2004 Feb; 45(2):377-80. PubMed ID: 15101727
[TBL] [Abstract][Full Text] [Related]
23. Activin A stimulates IkappaB-alpha/NFkappaB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors.
Sugatani T; Alvarez UM; Hruska KA
J Cell Biochem; 2003 Sep; 90(1):59-67. PubMed ID: 12938156
[TBL] [Abstract][Full Text] [Related]
24. Identification and characterization of the precursors committed to osteoclasts induced by TNF-related activation-induced cytokine/receptor activator of NF-kappa B ligand.
Mochizuki A; Takami M; Kawawa T; Suzumoto R; Sasaki T; Shiba A; Tsukasaki H; Zhao B; Yasuhara R; Suzawa T; Miyamoto Y; Choi Y; Kamijo R
J Immunol; 2006 Oct; 177(7):4360-8. PubMed ID: 16982870
[TBL] [Abstract][Full Text] [Related]
25. Distinct osteoclast precursors in the bone marrow and extramedullary organs characterized by responsiveness to Toll-like receptor ligands and TNF-alpha.
Hayashi S; Yamada T; Tsuneto M; Yamane T; Takahashi M; Shultz LD; Yamazaki H
J Immunol; 2003 Nov; 171(10):5130-9. PubMed ID: 14607912
[TBL] [Abstract][Full Text] [Related]
26. [Bone disease in multiple myeloma and its mechanism].
Abe M
Clin Calcium; 2006 Apr; 16(4):565- 71. PubMed ID: 16582506
[TBL] [Abstract][Full Text] [Related]
27. Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro.
Chikatsu N; Takeuchi Y; Tamura Y; Fukumoto S; Yano K; Tsuda E; Ogata E; Fujita T
Biochem Biophys Res Commun; 2000 Jan; 267(2):632-7. PubMed ID: 10631114
[TBL] [Abstract][Full Text] [Related]
28. Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function.
Jimi E; Akiyama S; Tsurukai T; Okahashi N; Kobayashi K; Udagawa N; Nishihara T; Takahashi N; Suda T
J Immunol; 1999 Jul; 163(1):434-42. PubMed ID: 10384146
[TBL] [Abstract][Full Text] [Related]
29. IL-3 acts directly on osteoclast precursors and irreversibly inhibits receptor activator of NF-kappa B ligand-induced osteoclast differentiation by diverting the cells to macrophage lineage.
Khapli SM; Mangashetti LS; Yogesha SD; Wani MR
J Immunol; 2003 Jul; 171(1):142-51. PubMed ID: 12816992
[TBL] [Abstract][Full Text] [Related]
30. Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.
Nguyen AN; Stebbins EG; Henson M; O'Young G; Choi SJ; Quon D; Damm D; Reddy M; Ma JY; Haghnazari E; Kapoun AM; Medicherla S; Protter A; Schreiner GF; Kurihara N; Anderson J; Roodman GD; Navas TA; Higgins LS
Exp Cell Res; 2006 Jun; 312(10):1909-23. PubMed ID: 16600214
[TBL] [Abstract][Full Text] [Related]
31. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity.
Yaccoby S; Pearse RN; Johnson CL; Barlogie B; Choi Y; Epstein J
Br J Haematol; 2002 Feb; 116(2):278-90. PubMed ID: 11841428
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: involvement of IFN-gamma possibly induced from non-T cell population.
Nagata N; Kitaura H; Yoshida N; Nakayama K
Bone; 2003 Oct; 33(4):721-32. PubMed ID: 14555278
[TBL] [Abstract][Full Text] [Related]
33. NMDA glutamate receptors are expressed by osteoclast precursors and involved in the regulation of osteoclastogenesis.
Merle B; Itzstein C; Delmas PD; Chenu C
J Cell Biochem; 2003 Oct; 90(2):424-36. PubMed ID: 14505357
[TBL] [Abstract][Full Text] [Related]
34. Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand.
Lee CK; Lee EY; Chung SM; Mun SH; Yoo B; Moon HB
Arthritis Rheum; 2004 Dec; 50(12):3831-43. PubMed ID: 15593184
[TBL] [Abstract][Full Text] [Related]
35. Curcumin (diferuloylmethane) inhibits receptor activator of NF-kappa B ligand-induced NF-kappa B activation in osteoclast precursors and suppresses osteoclastogenesis.
Bharti AC; Takada Y; Aggarwal BB
J Immunol; 2004 May; 172(10):5940-7. PubMed ID: 15128775
[TBL] [Abstract][Full Text] [Related]
36. Do human myeloma cells directly produce the receptor activator of nuclear factor kappaB ligand (RANKL) or induce RANKL in the bone marrow microenvironment?
Giuliani N; Colla S; Rizzoli V; Barillé-Nion S; Bataille R
Cancer Res; 2004 Jan; 64(2):772-3; author reply 774-5. PubMed ID: 14744797
[No Abstract] [Full Text] [Related]
37. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis.
Kotake S; Udagawa N; Takahashi N; Matsuzaki K; Itoh K; Ishiyama S; Saito S; Inoue K; Kamatani N; Gillespie MT; Martin TJ; Suda T
J Clin Invest; 1999 May; 103(9):1345-52. PubMed ID: 10225978
[TBL] [Abstract][Full Text] [Related]
38. Interaction of Fas ligand and Fas expressed on osteoclast precursors increases osteoclastogenesis.
Park H; Jung YK; Park OJ; Lee YJ; Choi JY; Choi Y
J Immunol; 2005 Dec; 175(11):7193-201. PubMed ID: 16301623
[TBL] [Abstract][Full Text] [Related]
39. Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells.
Mancino AT; Klimberg VS; Yamamoto M; Manolagas SC; Abe E
J Surg Res; 2001 Sep; 100(1):18-24. PubMed ID: 11516200
[TBL] [Abstract][Full Text] [Related]
40. CC-chemokine ligand 20/macrophage inflammatory protein-3α and CC-chemokine receptor 6 are overexpressed in myeloma microenvironment related to osteolytic bone lesions.
Giuliani N; Lisignoli G; Colla S; Lazzaretti M; Storti P; Mancini C; Bonomini S; Manferdini C; Codeluppi K; Facchini A; Rizzoli V
Cancer Res; 2008 Aug; 68(16):6840-50. PubMed ID: 18703490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
